Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

Inclusion Criteria: * patient aged ≥ 5 years old and \< 18 years old * patient able to receive sonications and perform MRI studies without sedation * diagnosis of supra-tentorial primary malignant brain tumor (e.g. malignant glioma, embryonal tumor including ATRT, ependymoma) * recurrence or progression of brain tumor after at least a first line of standard treatment (multifocal tumors and metastatic disease allowed) * indication of treatment with carboplatin, validated in multidisciplinary meeting * Karnofsky performance scale index (patients ≥ 16 years old) or Lansky performance status (patients \< 16 years old) \> 50% (a patient with a performance status score altered by a motor deficit due to tumor infiltration will be allowed to be included) * no threat of brain herniation or uncontrolled intracranial hypertension * corticosteroids treatment ≤ 1mg/kg/day * neutrophils \> 1.5 x 109/L * platelets \> 100 x 109/L * total bilirubin \< 1.5x upper limit of normal, AST et ALT \< 2.5x upper limit of normal * serum creatinin \< 1.5x upper limit of normal for the age or creatinine clairance \>70mL/min/1.73m2 (EDTA method or 24h urine) * coagulation parameters in the normal limits for age (fibrinogen, prothrombin time and activated clotting time) * no grade 2 or more toxicity depending on the NCI-CTCAE v5.0 criteria * no healed wound on the scalp * covered by health insurance * for patients of chilbearing age (15-17 years old) : a negative pregnancy test and an efficient method of …